World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
60
Citations
12584
World Ranking
11978
National Ranking
5142

Overview

Mark A. Tomai is affiliated with 3M in the United States. Their research primarily spans Medicine and Immunology and Microbiology, with significant focus in related subfields such as Immunology, Infectious Diseases, Virology, Epidemiology, and Molecular Biology.

The scientist's work encompasses a range of topics centered on immune system mechanisms and infectious diseases. Main research topics include SARS-CoV-2 and COVID-19 research, HIV research and treatment, immune cell function and interaction, immunotherapy and immune responses, T-cell and B-cell immunology, vaccines and immunoinformatics approaches, and immune response and inflammation.

Mark A. Tomai has contributed to multiple papers in notable publication venues, including bioRxiv (Cold Spring Harbor Laboratory), Nature Communications, Science Immunology, Science Translational Medicine, and Frontiers in Immunology.

Representative papers include:

  • "New horizons in adjuvants for vaccine development," 2020, Current Opinion in Immunology
  • "Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses," 2021, Nature
  • "T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers," 2020, Nature Medicine
  • "3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates," 2020, Science Immunology
  • "SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung," 2021, Nature Communications

Frequent co-authors collaborating with Mark A. Tomai include:

  • Christopher B. Fox
  • David C. Montefiori
  • Barton F. Haynes
  • Kevin O. Saunders
  • Ralph S. Baric

Publication venues where their work frequently appears are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Science Immunology
  • Science Translational Medicine
  • Frontiers in Immunology

Main fields of study evident from their publication record are:

  • Medicine
  • Immunology and Microbiology

Key subfields contributing to their research output include:

  • Immunology
  • Infectious Diseases
  • Virology
  • Epidemiology
  • Molecular Biology

The researcher's work reflects a focus on vaccine development, immune response modulation, and combating infectious diseases such as HIV and COVID-19 through immunological approaches and adjuvant innovation.

Best Publications

  • Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

    Keith B. Gorden;Kevin S. Gorski;Sheila J. Gibson;Ross M. Kedl

  • Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

    Sheila J Gibson;Jana M Lindh;Tony R Riter;Raymond M Gleason

  • Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.

    Hirotake Suzuki;Binghe Wang;Gulnar M Shivji;Paola Toto

  • A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod

    Stephen K. Tyring;Istvan Arany;Margaret A. Stanley;Mark A. Tomai

  • Cytokine induction by the immunomodulators imiquimod and S-27609.

    Traci L. Testerman;John F. Gerster;Linda M. Imbertson;Michael J. Reiter

  • Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.

    Tamara L. Wagner;Cory L. Ahonen;Aimee M. Couture;Sheila J. Gibson

  • Development of a Topically Active Imiquimod Formulation

    John L. Chollet;Michael J. Jozwiakowski;Kenneth R. Phares;Michael J. Reiter

  • The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

    John P Vasilakos;Mark A Tomai

  • VACCINE ADJUVANT PREPARATIONS

    Bernstein David I;Harrison Christopher J;Miller Richard L;Tomai Mark A

  • Pharmaceutical gel formulation for topical administration of 4-amino-2-ethoxymethyl-{alpha}, {alpha}-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol

    Beaurline Joseph M;Roddy Patrick J;Tomai Mark A

  • Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.

    Kevin O. Saunders;Esther Lee;Robert Parks;David R. Martinez

  • Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

    John P. Vasilakos;Rose M.A. Smith;Sheila J. Gibson;Jana M. Lindh

  • Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463

    Linda M Imbertson;Joseph M Beaurline;Aimee M Couture;Sheila J Gibson

  • Cytokine induction in mice by the immunomodulator imiquimod

    Michael J. Reiter;Traci L. Testerman;Richard L. Miller;Charles E. Weeks

  • Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.

    K Megyeri;W C Au;I Rosztoczy;N B Raj

  • The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.

    Robert P. Burns;Barbara Ferbel;Mark Tomai;Richard Miller

  • The antiviral activity of Toll-like receptor 7 and 7/8 agonists.

    Richard L Miller;Tze-Chiang Meng;Mark A Tomai

  • Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

    Kevin S. Gorski;Emily L. Waller;Jacqueline Bjornton-Severson;John A. Hanten

  • Immunomodulating and antiviral activities of the imidazoquinoline S-28463

    Mark A. Tomai;Sheila J. Gibson;Linda M. Imbertson;Richard L. Miller

  • Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609

    Sheila J. Gibson;Linda M. Imbertson;Tamara L. Wagner;Traci L. Testerman

Frequent Co-Authors

David C. Montefiori
David C. Montefiori Duke University
David I. Bernstein
David I. Bernstein University of Cincinnati
Margaret Stanley
Margaret Stanley University of Cambridge
Barton F. Haynes
Barton F. Haynes Duke University
S. Munir Alam
S. Munir Alam Duke University
Ofer Levy
Ofer Levy Boston Children's Hospital
Bali Pulendran
Bali Pulendran Stanford University
Ralph S. Baric
Ralph S. Baric University of North Carolina at Chapel Hill
Celia C. LaBranche
Celia C. LaBranche Duke University
Kevin O. Saunders
Kevin O. Saunders Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Mark A. Tomai

Trending Scientists

Recently Published Articles